Clinical Practice Session
Cardio-Kidney Protection with SGLT2 Inhibition and Beyond - Honoring George Bakris
October 24, 2024 | 10:30 AM - 12:30 PM
Location: Ballroom 20A, Convention Center
Session Description
This session reviews critical updates for the management of diabetic kidney disease and recommends how to implement new therapies. This session honors Dr. George Bakris who was an internationally renowned nephrologist and expert in hypertension and diabetic kidney disease.
Microphones will not be available during Q&A periods in this session. Please click here to submit your questions during the session.
ASN thanks the ASN Diabetic Kidney Disease Collaborative Task Force for assistance with this session.
Learning Objective(s)
- Summarize new clinical data in the field of SGLT2 inhibitors
- Discuss aldosterone antagonism in diabetic kidney disease, from trial data to implementation
- Describe incretin therapies, including single, double, and triple agonists, and their role in kidney protection
- Discuss the American Heart Association statement on cardiovascular-kidney-metabolic syndrome and implement the new recommendations
Learning Pathway(s)
- Diabetic Kidney Disease
- Hypertension and Cardiorenal Disorders
Moderators
Presentations
- Evidence for Use of SGLT2 Inhibitors and Translation to Practice
10:30 AM - 11:00 AM
- How Will the Incretin Data "FLOW" into Practice
11:00 AM - 11:30 AM
- Nonsteroidal Mineralocorticoid Receptor Antagonists, Aldosterone Antagonism, and Kidney Protection: Making It "EASi" for the Kidneys
11:30 AM - 12:00 PM
- Integration of the American Heart Association Cardiovascular-Kidney-Metabolic Paradigm into Patient Care: Challenges and Opportunities
12:00 PM - 12:30 PM